The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The spectrum of complement alternative pathway‐mediated diseases
Abstract
Summary: The complement system has once again come into prominence in the therapeutic development arena. The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target. Preclinical studies using animal models and human‐derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations. Major efforts continue to define the most optimal means to block complement activation in a cost‐effective manner. Because the system is initiated through three pathways and generates at least six immunoregulatory and pro‐inflammatory mediators, there is substantial complexity to this problem. One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclinical disease models. Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly associated with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age‐related macular degeneration. This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 3×
“Thus, although the anti-C5 mAb eculizumab is an approved therapy for this disease (2), additional therapeutic effects may be found by inhibition of the alternative pathway.”
Background
Cited by
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Complement control protein factor H: The good, the bad, and the inadequate
Ferreira, V. P., Pangburn, M. K., & Cortés, C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.007 · Cited by 420
The complement system in systemic autoimmune disease
Chen, M., Daha, M. R., & Kallenberg, C. G. M. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.014 · Cited by 327
Metadata
- Authors
- Holers, V. M.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2008-06
- Volume
- 223
- Issue
- 1
- Pages
- 300-316
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2163295341
- Cited by
- 195
- References
- 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The spectrum of complement alternative pathway‐mediated diseases. https://app.cochat.ai/papers/10.1111/j.1600-065x.2008.00641.x
- The paper
- Holers, V. M. (2008). The spectrum of complement alternative pathway‐mediated diseases. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2008.00641.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.